All
All
Parallel
Title
Appellant
Respondent
Lawyer
Parallel Search is an AI-driven legal research functionality that uses natural language understanding to find conceptually relevant case law, even without exact keyword matches.
Hi, I'm AMICUS. Your GPT powered virtual legal assistant.
Let's chat.
Log in
Sign Up
Select Country
India
UK
&
Ireland
AMICUS AI
CaseIQ
Keyword Research
Parallel Search
Browse
Commentaries
Columns
My Project
New chat
Federal
U.S. Supreme Court
Federal Circuit
1st Circuit
2d Circuit
3d Circuit
4th Circuit
5th Circuit
6th Circuit
7th Circuit
8th Circuit
9th Circuit
10th Circuit
11th Circuit
Court of Appeals for the D.C. Circuit
Board of Immigration Appeals
Special Courts
Bankruptcy
State
Alabama
Alaska
Arkansas
Arizona
California
Colorado
Connecticut
Delaware
District Of Columbia
Florida
Georgia
Guam
Hawaii
Iowa
Idaho
Illinois
Indiana
Kansas
Kentucky
Louisiana
Massachusetts
Maryland
Maine
Michigan
Minnesota
Missouri
Mississippi
Montana
Nebraska
North Carolina
North Dakota
New Hampshire
New Jersey
Northern Mariana Islands
New Mexico
Nevada
New York
Ohio
Oklahoma
Oregon
Pennsylvania
Puerto Rico
Rhode Island
South Carolina
South Dakota
Tennessee
Texas
Utah
Virginia
Vermont
Washington
Wisconsin
West Virginia
Wyoming
42 C.F.R. § 447.512 : Public Health — CENTERS FOR MEDICARE & MEDICAID SERVICES, DEPARTMENT OF HEALTH AND HUMAN SERVICES — MEDICAL ASSISTANCE PROGRAMS — PAYMENTS FOR SERVICES — PAYMENT FOR DRUGS — Drugs: Aggregate upper limits of payment
Text
(a)
Multiple source drugs.
Except for brand name drugs that are certified in accordance with paragraph (c) of this section, the agency payment for multiple source drugs must not exceed, in the aggregate, the amount that would result from the application of the specific limits established in accordance with §447.514. If a specific limit has not been established under §447.514, then the rule for "other drugs" set forth in paragraph (b) of this section applies.
(b)
Other drugs.
The agency payments for brand name drugs certified in accordance with paragraph (c) of this section and drugs other than multiple source drugs for which a specific limit has been established under §447.514 must not exceed, in the aggregate, payment levels that the agency has determined by applying the lower of the following:
(1)
AAC plus a professional dispensing fee established by the agency; or
(2)
Providers' usual and customary charges to the general public.
(c)
Certification of brand name drugs.
(1)
The upper limit for payment for multiple source drugs for which a specific limit has been established under §447.514 does not apply if a physician certifies in his or her own handwriting (or by an electronic alternative means approved by the Secretary) that a specific brand is medically necessary for a particular beneficiary.
(2)
The agency must decide what certification form and procedure are used.
(3)
A check off box on a form is not acceptable but a notation like "brand necessary" is allowable.
(4)
The agency may allow providers to keep the certification forms if the forms will be available for inspection by the agency or HHS.
42 C.F.R. §447.512
72 FR 39239, 7/17/2007, as amended at 75 FR 69597, 11/15/2010; 81 FR 5347, 2/1/2016
×